Anthropic Discusses Frontier AI Model Mythos With Trump Administration Despite Pentagon Ban 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Chinese Cars in Europe: Consumer Trust Is Shifting Fast 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Meta Is Building an AI Version of Mark Zuckerberg to Interact With Employees 
Baker Hughes Sells Waygate Technologies to Hexagon for $1.45 Billion 
Nissan Plans Major Lineup Cuts and AI Expansion in Bid for Global Sales Recovery 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
SAN RAMON, Calif., June 13, 2017 -- SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery needs, today announced that Jonathan M. N. Rigby, President and Chief Executive Officer, will present at the 2017 JMP Securities Life Science Conference on Tuesday, June 20, 2017. During the presentation, Mr. Rigby will provide an overview and update on the company's business including the development of its lead drug product candidate Trevyent®, that is in development to treat Pulmonary Arterial Hypertension (PAH).
Date: Tuesday, June 20, 2017
Time: 1:30 pm ET
Location: New York, NY
An audio webcast of the Company’s presentation will be available online at SteadyMed’s website www.steadymed.com. A replay of the presentation will be available for 90 days.
Investors attending the conference who are interested in meeting with Mr. Rigby may request a meeting by contacting their JMP Securities representative, or Lee Roth of The Ruth Group at [email protected].
About SteadyMed
SteadyMed Ltd. is a specialty pharmaceutical company focused on the development of drug products to treat orphan and high value diseases with unmet parenteral delivery needs. The company's lead drug product candidate is Trevyent, a development stage drug product that combines SteadyMed's pre-filled, sterile, single use, disposable, PatchPump® infusion system, with treprostinil, a vasodilatory prostacyclin analogue to treat pulmonary arterial hypertension (PAH). SteadyMed intends to commercialize Trevyent in the U.S. and has signed an exclusive license and supply agreement with Cardiome Pharma Corp. for the commercialization of Trevyent in Europe, Canada and the Middle East. SteadyMed has offices in San Ramon, California and Rehovot, Israel. For additional information about SteadyMed please visit www.steadymed.com.
Contacts: Marylyn Rigby Senior Director, Investor Relations and Marketing 925-272-4999 [email protected] The Ruth Group Lee Roth (646) 536-7012 [email protected]
